CLSD - Earnings call 2 2023 | Clearside Biomedical, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Clearside Biomedical Second Quarter 2023 Financial Results and Corporate Update Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Jenny Kobin, of Investor Relations.

You may begin.

Jenny Kobin

Good afternoon, everyone, and thank you for joining us on the call today.

would will remind statements. be I today's that begin, we call, making we like you to during Before certain forward-looking remarks prospects during future make Securities Litigation purposes that about of Private Various company's XXXX. Act the of this the expectations, forward-looking constitute call and Reform statements for plans we

our materially Form the indicated of SEC may by quarter filings for available factors, important Actual and Risk various XXXX, ended XXXX, statements section those forward-looking December our our on for June differ ended our on including results in annual these the year from quarterly other XX, those the discussed XX-K Form Factors of result report as XX, a XX-Q on report website.

views be of should today our In as date. of relied as as views addition, not any any our subsequent representing and statements upon forward-looking represent

update call, After elect disclaim if statements While remarks, our today's On any to Officer. George and for Chief Executive Charlie Financial we to Deignan, formal Officer; the specifically our do your obligation we these the so even call Lasezkay, our open we future, questions. change. we will Chief our forward-looking may have views in

call to like would George. I now over to turn the

George Lasezkay

X last Thanks, Jenny. the to Clearside that the space. leader is have The months in demonstrated clear suprachoroidal agents delivering

field, to a retinal suprachoroidal multiple able and patented small deliver space the targeting We're proprietary have microinjector. molecules visual We therapy injection our technology utilizes diseases. SCS that gene behind

development XIPERE, we SCS collaborations an delivery We research early-stage as have only validating pipeline. external the have as X product first SCS and and and FDA-approved well with internal

is indications wet dollar CLS-AX potential clinical million continues partners, the delivered axitinib grow our both lead targeting now into in utilizing our program ongoing there is versatile AMD. SCS different our together internally multibillion market suprachoroidal development for with space. therapies. Clearside Importantly, suspension therapeutic and with development licensing expand our opportunities, as X CLS-AX, proprietary trials X are our partners, the of internal to platform X we --

and this patients moment So in suffering believe large due let a of market result crowded me can we take the the population, opportunity make difference the growing to a about truly lives particularly millions the of from as products, the the of to is why disorder. Wet U.S. we market talk development arena mainly and the new a of AMD aging for a in

treatment may patient their for a compliance that frequent well outcomes. CLS-AX numerous office and with CLS-AX be burden to the main who visits has on dosing treatment based maintenance less is wet dosing AMD. maintain with potential currently differentiating treatment a With therefore, be per vision better require patients EYLEA recently marketed times AMD, recommended In year their times XX be patients reducing year, up room to higher to dosed including a X for for provide Lucentis year. X treatments wet improvement burden up the and VABYSMO twice the that believe is demand, times CLS-AX may we X patient approved patients This onerous matters documented there products and new existing the factors. caregivers. Based option for that a option is and significant current over to where a treatment frequent existing achieve for on X for contrast, because the it drugs. treatment milligrams, a label reduce therapies, has could approved a improved challenge, been year

delivering most potency kinase studies. First, preclinical potent times highly is and inhibitor, other XX than tyrosine the which CLS-AX utilizes axitinib, more TKIs

to a physicians delivery not has that This a Second, proprietary favorable and and OASIS our SCS safety be trial, in CLS-AX safe demonstrated eye. It's Phase I/IIa administered does clinical surgery And proven inflammation. CLS-AX no insert implant we administration and does commercially multiple office in thirdly, into with mechanism our in profile not reliable, signs showed of require and the both of trials. clinical an using by is require microinjector. it suprachoroidal their delivered single

extension terms months need CLS-AX, treatment the participants duration In of of or cohorts did with Oasis single X/X X a supplemental study in the more. for of in not dose dose of higher

a Also, they measured these during OASIS to the XX% X-month participants months period reduction burden prior entering X to the trial. experienced XX% of number treatment anti-VEGF the in to by treatments the as received compared

subfield corrected observed also CST. mean effect acuity best stable of mean we Importantly, BCVA visual stable biological central with and thickness or signs or

the safety, of initiated multicenter with efficacy results we is to ODYSSEY, trial drug double-masked, The of the and with guidance and objective development OASIS Phase evaluate participants following participants for promising CLS-AX randomized IIb treatment and the clinical AMD. FDA for overall wet duration the our AMD. AMD, for by quarter, in Encouraged treatments last draft wet wet trial

The EYLEA trial aflibercept. other arm the in is the standard of current care, or

to trial demonstrate dosing visual lower Our CLSA and desired to with goals for similar a or treatment Phase AMD obtain to determine clinical are necessary development CLS-AX III the the clinical ODYSSEY the data exon acuity a burden for fixed program. regimen outcomes a wet

the planned. enroll we nearly been all a trial. to receive of to either randomized of are open participants the is XX solid CLS-AX or in Multiple eager to our be planned have trial part is the sites currently trial, and off been Clinical sites have pleased to that have aflibercept. start We participants and progressing trial as

administered for in assessment weeks. In be as injection. XX-week BCVA and well intravitreal microinjection the Clearside's or will tolerability aflibercept trial, administered in reminder, randomized that is a XX CLS-AX be measures randomization expected treatment means period mean of a period the are total by suprachoroidal of the milligrams for expected enroll SCS will either X:X aflibercept safety This of as be The total CLS-AX. change over milligram primary X a a by to the to participants exon XX XX in is is there the trial on. schedule. and Odyssey aflibercept injection participants As CLS-AX X participants The outcome XX the and to using CLSA of the

treatment visual anatomy Odyssey ocular as injections, measurements therapy other such by the burden is need as measured the trial CST. One supplemental including and outcome changes and criteria. component eligibility over function of important total duration for are secondary The the in

Our our to with likely trial inclusion that treatment confirmation experienced of Eligible disease. masked from will diagnostic is that level therapy. disease at by their ensure This be persistent reading center screening. to benefit in of designed and active visit imaging need have criteria undergo to is will of participants participants are ensure screening active and treatment respond of treatment in specificity anti-VEGF followed participants will

for further wet with assessment of visual of ability advantages the will CLS-AX this order proper the CLS-AX AMD. potential demonstrate the patients maintain believe with will a in action allow We of AMD. longer treatment believe the acuity to We reduce one patients in with to burden duration

XXXX. confident the line design and of in third overall quarter success data are forward our the in reporting potential top we in We Odyssey, trial and to look

Moving on to XIPERE.

continue regarding feedback from to We receive the positive XIPERE of use clinicians with patients.

in learn SCS with injection Our date. report & that Lomb North product XIPERE been more sessions Bausch training providers well commercial highly to These and partner associated microinjector edema treating and effective of American that easy utilizing specialists with the care procedure for and with continues suprachoroidal patients received. Physicians for sessions than XIPERE, uveitis. attended health is education to trained to is macular have retinal conduct X,XXX the well

with parameters country working focused forward, is & physicians patients. on uveitis reimbursement engagement for on Bausch simpler make XIPERE will specialists across the and to for increasing Looking that use their Lomb it

to Arcadis. Asia of Our forward to as XIPERE, in they which Vision, continues with their Pacific refer partner, development Arctic move X indications

trial For in first edema, data the Vision indication enrolling China. uveitic will If Phase China. positive, the approval currently in of to allow for is Arctic confirmatory macular III apply Arctic a marketing

its suprachoroidal Australia of validation an has drug of being innovative drug of of application NDA of acceptance the of In step Arcadis form for Goods The commercialization another suprachoroidal the addition, uveitic recognized accepted the XIPERE. macular and Arctic that towards Therapeutic new formally in ophthalmic recently the announced for the edema. delivery treatment an Administration Australia administration additional is use global of

clinical edema. them indications. for indication the second look is Arctic forward use Vision could of to expand made the other we and later them. trial, data broadening updates macular further to This The a about year. XIPERE from the this the expect to insight Arctic excited we of the report and the has trial Phase provide diabetic Arctic data completed I use has of progress in XIPERE in potential We're helpful from

with closely this diabetic our program our We SCS on to ocular delivery in AMD Earlier partners also treatment its with of wet gene and therapy developing AbbVie. RGX-XXX oncology deliver microinjector. announced continue retinopathy collaboration the suprachoroidal ABBB developed utilizing for treatment and updates being to REGENXBIO month, with work technologies breakthrough

delivery suprachoroidal steroid resulted administered cases inflammation. of presented trials, Phase of REGENXBIO II patients the July, altitude X interim with In eye and demonstrating AVX from to data drops in intraocular prophylactic XXX

X the of meeting from in REGENXBIO Additional Hawaiian interim Retina data from American in efficacy on next trial planned in AMD in be months. Interim over Academy AVA from at presented is data efficacy to January XXXX. is the and both data of the trial the November trials Meeting wet retinopathy and Ophthalmology the for I is diabetic XXXX the ALTITUDE expected expected

Biosciences, melanoma. for Bel-sar Aura treatment their Our the their week oncology announced choroidal last candidate drug progress partner, of with

primary a with comparing Their is global time as endpoint in sites in globally Bel-sar Aura sham enroll trial patient multiple to to the trial ready progression. and trial dose with the U.S. XXXX first second sites versus expected to the has the clinical is of Phase III as half tumor designed patients superiority qualified

in II patients III XX regimen include used the updated will the Phase addition, expects XXXX. therapeutic In data intended half follow-up the data Aura Phase present be in global months of efficacy treated The with median trial. to second to of

turn now over a Deignan, summary of programs, financial that to our Charlie With update. for call CFO, I'll the our

Charlie Deignan

afternoon, you, everyone. George, and Thank good

and Our of earlier release just were available press would second financial provide summary on a results financial website. status. the I in are Therefore, for our quarter our published our

cash As cash of and XX, our XXXX, equivalents $XX totaled million. June approximately

our year. sufficient worked into we we to move resources now budget We to outlook, the prudently third programs, operations manage planned to fund have our Based our on next with over fine-tune to as our continue of current cash and we XXXX. have expect our forward quarter the

September forward progress. I and investor conferences, including Healthcare Conference Conference remarks. to forward for the We months, few the updated look now in Healthcare call Jones keeping Global look our several over We the will his Summit participating our in came turn you Wainwright we H.C. in George over that Wednesday back Trading this October. on -- to to next Ophthalmology the closing

George Lasezkay

to Thanks, large suprachoroidal unique a closing, of delivery market Charlie. globally. is opportunity advance technology action Microinjector. new continues wet inhibition our a CLS-AX using AMD in our and suprachoroidal In mechanism with injection targeting pan-VEGF state-of-the-art a utilizing SCS

offer to will CLS-AX in IIb the Phase trial while burden vision frequent the are We their our for a reducing confident therapy of design patients that ODYSSEY and potential injections. maintain

partners current as programs. Our progress respective clinical encouraging their and are well across making reporting meaningful data

on of We SCS continue the our and to delivery to drug the microinjector potential receive advantages suprachoroidal feedback space. positive

We of back-of-the-eye at treatment community discussions very scientific field opinion leaders the visual diseases. behind Clearside treat drug with in key active delivery the retinal the remain ongoing within pioneered to meetings disorders. in medical and has

technology continue expand opportunities to of to the platform. will explore We injection use our suprachoroidal

like to the for the Now call I'd operator questions. open

Operator

[Operator from with is Jon Securities. Instructions] Our first question coming JMP Wolleben

Jonathan Wolleben

for me, George. couple A

many you are good add You far you also, number, tell patients then you still commented more, you been that if study? how are you'll think And mentioned XX Can think open that the sites enough. now. in us about if almost dosed have so I being Wondering you have dosed. feel

George Lasezkay

was Jon, comfortable to with close our XX, feel and we're XX. XX. We goal very Okay.

is that's just about and We there. But XX, over few have XX may interest. now, a a We goal possible. our right we're lot enroll extra of

So very with that. we're feeling good

reported of updates, that the we terms process. begun randomization In have we've

not we've between we're be arm in of at patients actual in had updates CLS-AX arm. So number the point on the aflibercept giving trial. the this But patients the multiple randomized and time,

Jonathan Wolleben

be someone about the re-dosed rescue data. Odyssey with wondering based your EYLEA many OASIS then And the CLS-AX CLS-AX about interesting think the you criteria. with or ability nuance for patients on rescued modeling Okay. do depending is hits in when design will how I'm on to re-dose

I us think lot of give We're from this TKI going not to interesting could a get information. other studies.

George Lasezkay

patients very this this weeks in the of than trial X-month is be that And I of designed treatment. -- we're majority hopeful think vast We one. are XX CLS-AX degree getting and the some I'm there getting of success from to lot to less we've listen, very months. of don't expect unless in be the have a -- a X surprised I we any deviations protocol, would I towards if that way rescues we going believe, be a to a success have in X- Yes. high

in our X early second you first -- expectation at got stage XX remember, doses -- dose, any, loading and dose less loading CLS-AX few, very CLS-AX we've dosing if we're There weeks aflibercept. if rescues the than there's after is which that the the of

label before then to least X CLS-AX of And both doing for arm. in going with we're CLS-AX earlier. is every the really dose the initial any after anticipate on. We're weeks patients in switching significant months months at the XX X to going of groups -- But therapy unless label in aflibercept on we're being So dosed every loading. being I number on terms They're rescued supplemental required test. don't aflibercept

Again, we data OASIS -- to The the gives that OASIS the encouragement. kind run us data really -- trial. of have really is think I

out we saw carry to the on and what I OASIS, to the in the according according very protocol -- few. be do But to have run protocol. trial think there'll we if the based We

Jonathan Wolleben

opportunity Can versus at and with hop about potentially in back in a And a population talk I'll you looking the extend treat for subsequent study? queue. the treatment-naive CLS-AX

George Lasezkay

you again? just that. that last I repeat missed Okay. part real quick. just of Jon, the Could

Jonathan Wolleben

a and How study? opportunity potentially subsequent or do you're at like now a studying extend the about population you treat in looking think treatment-naive

George Lasezkay

going Well, X arm make in earlier. that the require gets said, they CLS-AX a we're at to dose like didn't months, I everybody one if sure

CST at really real don't that X I changes by and that it. think there looking hope of will being that people our treated changes BCVA require at be virtue are months is

So indicators really need. multiple therapy, they the looking but at to anatomical we're the to going be biological met able at looking dose also out report being a indicators, a it we're and was whether

Phase what to into with fixed trying a to that go proper do dose physicians has into really I believe so fixed we III. And regimen, dosing dosing to to And here Phase go extend. used is quite often because what trying is Aflibercept determine a the fixed and need we're but regimen. III treat to

the going They're are patients office be every coming into think coming to office. year I They're once months, a couple going a every or twice year. the going of back be other to come to into not month.

clearly, after people approved, X I a a now fixed of look months to months X you at on-label maximum. every where can the seeing think VABYSMO, other even any in people I opening dosing at I'm just practice, a dose CLS-AX which is regimen every CST and just in And stable we doing that will there's after loading stable, not with months that's mentioned the be sure completely months. in your look if doses or number be is if mean, getting was come comfortable they recently X if their extend. approved really it if I And their was dose that feel it BCVA forward that responsive and is have like in dosed at treatment to to and X but therapy as remarks. I question, X

we're that -- to X that's I treat a for think category, X X- doctors the to will if think And in point, still that. even patients. past and to improvement extend X-month major at look I

believe, we III, with it was rather So be we of the -- past see months X, past we regimen there's and we the we'll of than Phase fixed have -- go. far treat-and-extend how go X, I may a is the and to going into see number have in where in X really way kind dosing a patients. That done data,

is goal fixed dosing to really the up regimen. Our set

Operator

Argyrides with question Securities. Andreas next Our Wedbush is coming

Caroline Kimberly Pocher

for is This actually on Andreas. Caroline

George Lasezkay

see can't anything. Sorry, I

Caroline Kimberly Pocher

No okay. worries. It's

in And availability us. seeing ODYSSEY? from how progressing? second, powering ODYSSEY is Can discuss and the you just you time line impact VABYSMO? X any your the for targeted for you the enrollment of Are Just enrollment discuss from can assumptions then

George Lasezkay

Okay. a conducting not not Sure. conducting trial. powering The trial. a We're we're assumption, superiority non-inferiority

CST Can aflibercept to terms X the see So at patients in going assumption weeks, arm on there a those CLS-AX arm. and is in of the the then do week in keeping label. how BCVA -- aflibercept stable powering at really isn't here. look we're looking What and we're XX what over a

a And groups it Should think to a the be between and III. -- this as that longer a months? into powered it non-inferiority going maybe would X whether not every what particular. the do outcome, it So as basis there's okay? dosing set on that, see every trial the be would to and be every X sufficient regimen is up months, Should X we're trying to of similar you in go patients our what BCVA fixed not Phase are can ideal we has in than trial X a should is have months, CSTs be

trying we treatment this run III. the way Phase where II into II should We're of So a looking IIb standard and Phase an here go doing are consistent trial an the that patients trials with to a dosing. into in to think we're the here, in on Phase of been number well total looking how is that to fixed basis, very convert run. -- not arm we III estimation Phase terms We're design estimation compare in recent a a have on the Phase

XX in mentioned remarks, enrollment, as that the the targeted want. we're and sites release I in press of at the terms In we opening the nearly

have are We OASIS included our of from in all previous ODYSSEY. sites

going enrollment, to people what give disclosure not we when but with that think data out are per on in. we is regarding -- we're line to very se, not already CLS-AX be experienced are closing our be have very And soon. we So going top is then that changing We'll available. updates enrollment

to very of we're way going we and third still year on, still next quarter XXXX top see of data. terms with QX comfortable as line and participants looking enroll we've sites at able of the of in been We're enrollment

Caroline Kimberly Pocher

Okay. on Great. Congrats the progress.

George Lasezkay

you. Thank

Operator

Sean Our coming with Kim is next JonesTrading. question from

Sean Kim

likely injections and suprachoroidal intrinsically my is safety light I whether therapy please in effects? is of drug if thus might prone injections, issues been recent first guess first in reported a that to given any there has -- of of any to delivery with far? geographic question for retinal me less an question intravitreal escalators And remind the atrophy. more reported adverse suprachoroidal be Could approach related related comparison FDA-approved vasculitis us question causing retinal in with you or

George Lasezkay

certainly Well, CLS-AX, I as no think no of vasculitis. the inflammation, first I know, including far had kind events, retinal we've indication part question with as the first, of any of

the easy a injections. trained, experience very but been safe, patient very they once covering on it previous at to is it's acceptable or tyrosine and if reports that any procedure. We've So that have partners' as all of is at well from and repeatable -- inhibitor the not to and physicians experience very that sure, or in not SCS doesn't but I'd seen that. find retinal a any they're the significant trials trained and nothing it both don't itself intravitreal in our it training product as kinase reliable, problem. Certainly, I'm to reports be CLS-AX, the mind a long. any trained our check all to a procedure the microinjector, once significant And you that It's double as in getting far they're physician that itself, the was we to sense have look vasculitis. very XIPERE injection that a using injection our complicated, take there's that comparable procedure, of aware, injection comes it as procedure -- and that approved trials on find are important technique an

any or up come vasculitis our can retinal I recall partners' not that in clinical problem of trials So our trials. as a clinical has just

They've REGENXBIO in in they've be inflammation any trial, But of vasculitis. to Phase of was did the the retinal that not signs Now recently reports believe, of have had their and reported some inflammation seen I with no steroids some wet of heard in fair, has certainly trials. earlier AMD. topical II

Sean Kim

that is dosing And schedule Okay. of to That's ODYSSEY the define goals III. understand the fixed one helpful. if Phase for correctly ODYSSEY the for trial, trial the I related to potential

BCVA end question dosing across that change? So different efficacy it dictate my Or that is, totality it of the of would what III? would are Would tons? for be data point you more a be interval Phase

George Lasezkay

vision perspective, most certainly to from and want the Chambers or I endpoint -- preservation at and think very important FDA FDA's most the improvement. vision BCVA. the is important focused be vision on -- certainly the -- the would first point Dr. They foremost

the And CST important keep would kind So important so real the that's can think stable long BCVA like think for thing. of requiring important intervention? without there. that important, any factor stability BCVA the most but things duration. How the I factor be think Other we most the most supplemental I BCVA I are is

Sean Kim

you. And terms that follow-up for specifically change BCVA Okay. population your for the what ODYSSEY the just trial? might in curious on that expectations of be in a just Got target aflibercept months, is, quick the arm X to

George Lasezkay

I I'm would But that would would label outcome. I get much so hope. would -- not a regarding appropriately typical -- patients they'll with and sure that not on similar BCVA. patients the get they if have hope expect the dosed go and that aflibercept, I -- into are what that they expect to BCVA expect I

versus interval going what There'll using how as out we their turned know than as is VABYSMO the hands we I it be III. than be the as be to VABYSMO our we before against hands aflibercept think to longer well people. our did aflibercept we looked VABYSMO of did saw to how believe in III. aflibercept VABYSMO in But as different -- don't the that against that. that And in aflibercept overall any And Phase with seen aflibercept. control other at their you've in other against a did be outcome well dosing can similar would Phase dosed do against why people. labeled We

disease, And other similar seen enrolled what other patients you're really strong trials patients required Are may they AMD intervention enrollment, -- really in patients are the that than well does of signs difference you of in? patients the respond putting any with. you've that expect to it if active in down in population. have kind those to don't to a I begin what aflibercept of way really come So real going wet in not to do any putting aflibercept really, you are don't have because

And disease but there's for we'll a trying literature with that But lots enrolled. disease, X no no the of injections. are the will might have that active they're have active patients we're relatively when are of talk time to to diagnosed go make I that with pretty groups that signs between outcome think responsive aflibercept dry anti-VEGF about then be active of and signs people the but -- long consistent period sure disease history. group the And in of

Operator

is question & Needham next Our Rohit with Company. coming Bhasin from

Rohit Bhasin

sufficient is collaborations cash This ODYSSEY? Are SCS a the to top balance microinjector current evaluating us still of you for on get line Rohit And Serge. is then for new to platform? potential readout new the

George Lasezkay

first or conduct activities take development take about don't on those with regular useful, potentially I'll kind them might question, part We various that We suprachoroidally. ongoing agents think of in Yes, are jump discussions delivered the of business various we be states companies lightly. a basis. other right. into therapeutic that with we All partnering disease let in Charlie the second. and I'll

for positive We they're for strategic very very and a the sure want be company. to would us make positive and

strategy sure of in access partnering. our not example, Clearside. has right a we therapy in, of competency to that we the fits We make for it the for technologies collaborator gene terms, to And -- partner, the and right that we don't partner us have have so typically where we core expertise that any is areas cannot that need try

that's the we in to partner So gene -- partner in particular. or therapies look why the of area in

together companies to be there trying And be for that right certainly people for open with conversations we're other have put them. small our suprachoroidal well to makes of that. delivery to to But the other proprietary sense we that molecules into constant and us system, set put a that as want as deal are could

the cash runway I'll Charlie, take And let you all...

Charlie Deignan

-- our and want Rohit. cushion, to -- data I doing our finish we obviously, we come. But quarter, exactly will the continue and we our year, cash much -- can't Yes coming comes get past data said, extend our a to is look will Thanks, that's can of ways extend -- That's within next runway know now QX in, planned we're we as and so QX when at dilutive us and looking next enrollment, the we'd to is non-dilutive into year. -- our or to what until data the come all runway.

Operator

question Padovano is Our next coming Jack from with Stifel.

Jack Padovano

Jack is This calling Annabel. in for

or chance Just with some able partners? a any you some if again expected milestones question And go that Could over you them? for briefly might economics catalysts there's quick me. from of the your be to see additional near-term

George Lasezkay

something want that is to… you Charlie, would

Charlie Deignan

Sure. Yes.

announced milestones particular some revenues. But we them. these haven't Healthcare to when and milestones will But cap just -- the with Phase announce get go not allowed we milestones, that's with typically, but III, -- or we are getting collaborators don't that would affect into as our those that our there's reminder, have a to of as we're III towards development and So Royalty, up monetized HCR, go our wrapped royalties forget EPS pay. that Phase

from If -- pay have XXX we'll you $XX remember, so $XX.X million. that we back, to took them, million and approximately X.Xx

milestones HCR any come go programs... our -- on partnered those will in So that directly to

Operator

next is with Our coming Wainwright. question Yi H.C. Chen from

Yi Chen

don't some whether comment REGENXBIO know future candidate to on I can the become with BMD. their if partner, you potentially reported recently could their in Your CLS-AX... candidate for competitive progress

George Lasezkay

type we're therapy, I therapy that's I'll -- take different product Lucentis. There, anti-VEGF X. approach that circulating standard what therapy we're going the question. Lucentis understand blocking a -- cetera, long VABYSMO, I what therapy different than have, time perspective, their VEGF. our claim and to is much So CLS-AX suppose it EYLEA, generates From that taking is a the a I fame binding action think their et could. is is I their And potential a and It of REGENX again, pretty X a REGENX/AbbVie the it's the like receptors right? depends X, mechanism think as mechanistic -- in just does that would VEGF they're gene to molecule. last

years VEGF, including it's of cases, completely treatment which VEGF-A once neovascularization. of binding particular, they're therapy, not in find there's VEGF-A, can that overexpression CNE a couple VEGF bound, especially a potential on if circulating circulating after there's to an anti-VEGF-A you still patients any -- start again overexpression the many longer-term So cause of and VEGF-A. And an -- they're getting in

going So are I they spin on I want that think a could to we you after put think as that wet AMD while it. complementary competitive positive with it's they're in CLS-AX, be potentially if

I be complementary different. And of the tyrosine therapy. -- CNE, unlikely our theirs And mechanisms to in of block VEGF all to based unlikely using any that kinase inhibitor because cases, would resistant those would many mechanistically, anti-VEGF-A think become they'd overexpression patients mechanism VEGF X receptors. address are a while because through

of was sites. there the the we even So CNE, blocking if overexpression would of CNE be VEGF receptor at interaction

just room to therapy, be products. as that often the develop than to be used all up multiple X being where able patients. particular treat wet there's characteristics refer approaches, used cancer products it So for I the could rather competing I area products there's to this straight to And I cancer. up AMD end think think starting for for multiple of multiple together

see. for the clinical will think I proof in products. there's The both and both, room be for we'll data So

Yi Chen

if the prescription whether license your you to correlated prescription of know can quarterly don't and volume I is, XIPERE on question is revenue comment next My the volume?

George Lasezkay

that. handle I'll Okay. Charlie let

Charlie Deignan

Yes.

So we prescription have don't information.

those you get. difficult think retina to I drugs that track of

reporting they obligated with trends they So so the do out sales, to about on we publicly you start contractually sales discuss help can't until or give can't any that. I guidance to not were unless

Yi Chen

lastly, And of you time comment approval line on for -- potential the to it. your Got obtain partner in could to the Australia. XIPERE

George Lasezkay

filed approval our to States Well, -- filing ago. expectation should the be to of Australia month similar so very And or review is the typically it's understanding XX-month cycle. in a that your about they in a that it's United

United understand do guess by similar approval the And in would But about time for which on news Australian to be XX runs this an have time But my part. that's next months. think I the line so we process of they'll a it'd States, is kind educated about -- year.

Operator

of have session. end the reached We our question-and-answer

Lasezkay now back the will Dr. comments closing for over turn any have. you I to call may So

George Lasezkay

the you appreciate for on operator, can this Clearside. throughout continued really We you look Thank that, disconnect afternoon. your now We you in you, forward to all again, progress updating us all. call. Thank And year. at you. the Thank interest the joining our call on

Operator

concludes sir. you, today's Thank This conference.

lines your you we You for time, your may participation. disconnect this and thank at

Clearside Biomedical (CLSD) 14 Aug 232023 Q2 Earnings call transcript